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Introduction
The notion of using of replicating viruses as potential anti-cancer agents goes back over a century, with occasionally dramatic regressions of cancers following viral infections (1) (2) (3) (4) (5) (6) . Clinical responses were observed in preliminary studies using replicating wild-type viruses such as adenovirus (1) and mumps (5), However, progress faltered for a number of reasons: fears over safety; the lack of objective response criteria; lack of randomized trials; and the absence of Good Manufacturing Practice standards (1, 5, 6) .
Despite these reservations, oncolytic viruses (OVs) remain exciting prospective anti-cancer agents, because of reports of selective killing of tumor cells, (7, 8) .
There has been a recent resurgence of interest in OVs, based not only on fundamental advances in tumor and viral biology, but also the ability to scale-up manufacture of clinical grade viruses, and improved clinical trial designs (9, 10) .
Clinical development of oncolytic viruses
Modern trials commenced in the mid 1990s, administering OVs by a variety of routes, including intra-tumoral (IT), locoregionally and, more recently, intravenous (IV) routes (Table 1) .
Concerns over the safety of replicating OVs have eased, given the satisfactory treatment of several hundred patients within multiple early phase trials of RNA (reovirus, Newcastle Disease Virus (NDV), measles) and DNA (adenovirus, vaccinia, and Herpes Simplex Virus (HSV)) OVs (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . Typical local response rates observed after IT administration range from ~10-60% (14, 16, 17, 20, 23) , with the best objective radiological responses lower, at just under 30%, at best (20, 23) . Single agent IV treatment offers even lower objective responses, at <10% (12, 19, 21, 25) .
Commonly-observed side-effects include local reactions within injected tumor masses, following IT administration, and 'flu-like syndromes, following intravenous infusion. Edema, precipitating billiary tract obstruction and jaundice (22) , or bronchial obstruction and respiratory compromise (21) , represent serious adverse events and have led to trial protocols excluding patients where disease has the potential to cause critical obstruction (23) . [ Table 1 here]
A closer look at the reasons behind the difference between preclinical studies and the clinical experience may be the first step in realising the full anti-tumor potential of OVs. The clinical development of dl-1520 (Onyx-015) (26) , a wellcharacterised oncolytic adenovirus, which was first used over a decade ago, illustrates some of the challenges in developing OVs clinically.
Multiple clinical trials were completed in multiple tumor types and using various routes of administration (Table 1) . Objective local response rates were improved to >50% by combining Onyx-015 with chemotherapy in squamous cell cancer of the head and neck (SCCHN), hinting at synergy (15) . However an unreported, incomplete Phase III trial halted Onyx-015 clinical development (27) .
H-101, a closely related virus, has since found use as a licensed cancer therapy in China for SCCHN in combination with radiotherapy. Unfortunately H-101 approval is based on limited controlled trial evidence (27) , and a corruption Treated patients had a 58% one-year survival rate (23) historical Phase II survival rates of 25.5% (32) . Data from a Phase III trial in metastatic malignant melanoma patients are keenly awaited (33) .
The dsRNA reovirus (Type 3 Dearing),is safe and effective in early phase clinical trials employing IT (14, 34) , IV (25, 35) and combination (30, 36) approaches (Table 1 ). An on-going, randomised Phase III trial of reovirus, in combination with chemotherapy, in refractory SCCHN follows a recent phase 1/2 study where 8 of 19 HNSCC patients achieved an objective partial response (42%) (30) . Reovirus therefore represents another advanced contender in the race to enter the clinic (30, 36) .
[ Figure 1 here]
Oncolytic viruses and selective replication
Appreciating the rationale for the action of OV may help to put the role of the (41); and deletion of the adenoviral E1B gene, the product of which normally binds to and inactivates p53 e.g. Onyx-015/H101 used in SCCHN (26) .
Strategies for maximising the efficacy of OV therapy: exploiting the host immune system
A comprehensive review of the immune system in the context of OV therapy is beyond the scope of this article and has been summarised elsewhere (42, 43) . 
Preclinical adaptive immune response data
Pre-clinical work suggests that OVs may promote immune responses, which outweigh direct oncolysis in mediating anti-tumor efficacy (Table 2) [ Tables 2&3 here] Preclinical innate immune response data Data using clinically-relevant OVs demonstrate an intriguing relationship with the host innate system. OVs may be inactivated preventing direct oncolysis (Table 3) , but also show a potentially productive inflammatory anti-tumor response ( Table 2) other studies have shown the opposite effect, with inhibition of the innate response improving replication and therapeutic efficacy of HSV, vaccinia, and reovirus (53, (63) (64) (65) (Table 2 ). These differences underline the influence of experimental conditions. Ultimately, complex OV, tumor and immune interactions may not be adequately represented in present preclinical models, and clinical relevance may be best sought in a translational setting.
Clinical Immune data with OVs
Immune response data on OVs in clinical practice are limited, but give an indication of the host response to tumor and to OV alike. Available data relate to the phase-2 trial of GMCSF-expressing JS1/34.5-/47-/GM-CSF, described earlier 
sites, suggesting systemic dissemination of virus and direct oncolysis as a viable alternative mediator of tumor responses (22) .
Pre-clinical work with OVs raises questions of whether the traditional doseescalation approach is appropriate for early phase trials of OVs. Our own preclinical studies in murine melanoma models, suggest it may actually be counterproductive to administer the Maximum Tolerated Dose of OV, as this approach may encourage anti-viral, rather than anti-tumor, immunity (48, 49) (Table 3 CI values of <1, 1, and >1 indicate synergy, additive effect and antagonism respectively (72).
[ Table 4 here] The taxane chemotherapies (docetaxel and paclitaxel) consistently demonstrate strong synergistic activity (CI <1) in pre-clinical combination studies with a variety of OVs including adenovirus, reovirus and HSV (see table 4 ). There are various suggested mechanisms of synergy, perhaps reflecting the complex biology of OV and broad effects of chemotherapy. The microtubule-stabilizing action of taxanes appears to be important in facilitating reoviral and adenovirus replication (73, 74) .
Induction of apoptosis may be a common pathway for OV synergy with taxanes.
Reovirus-induced, caspase-dependent apoptosis is synergistically enhanced by the prolonged G2-M arrest induced by paclitaxel, in lung cancer cell lines.
Similarly synergistic apoptotic cell death results from the combination of HSV induced G1 arrest, and taxane G2-M arrest, in prostate cancer cells (75) . Paclitaxel sensitivity is also synergistically enhanced by vaccinia-induced release of type I IFN following viral infection, and high-mobility group protein B1 following cell lysis (76) . Finally, physical effects may play a part in synergy, as shown in pre-clinical studies in which the combination of oncolytic HSV and taxane chemotherapy resulted in cell lysis and breakdown of tumor, with improved ingress and replication of virus in tumor cells (77) . Other chemotherapies also show synergy, via similar mechanisms, e.g. cisplatin, which potentiates apoptosis in melanoma lines (78, 79) , however the wide-ranging, high-level, synergy observed between various OVs and taxanes, would support such combinations being explored clinically (Table 4) .
A recent report describes a systematic attempt to maximise synergy whilst retaining oncolytic ability (80). Diallo and colleagues describe a "pharmacoviral" screen, in which the impact of each of over 12,000 chemical compounds on viral oncolysis was assessed in a cell-based assay, using a high throughput screening method. The cytotoxicity of low titers of the VSV mutant, VSV-∆51, which is highly sensitive to the interferon response, was assessed, with and without drug, Reovirus combined with docetaxel has proven safe in a Phase I trial of 16 patients, with one objective complete response, 3 partial responses and 7 patients with stable disease observed (84) . Reovirus was detectable in tumor biopsies, and docetaxel did not compromise the neutralising antibody response to reovirus (NARA). In contrast, a similar early phase trial of gemcitabine combined with reovirus led to liver toxicity, and reduced NARA. Only one objective response was seen amongst 16 patients treated, plus 6 patients with stable disease (85) . Reovirus/taxane and reovirus/platinum combinations have also featured in a phase 2 study in relapsed SCCHN patients. Nineteen patients, most of whom were refractory to previous platinum-based chemotherapy, were treated with intravenous reovirus, along with carboplatin and paclitaxel chemotherapy with partial response rates over 40% and stable disease in a further 30% (30) . However, in contrast to the JS1/34.5-/47-/GM-CSF phase 2 data in melanoma (23) , no complete responses were observed, and though promising in terms of response rate, the small sample size and current lack of information regarding duration of response, do not immediately predict the 
success of chemo-virotherapy in this setting according to predictive algorithms (30, 86) . The result of a key ongoing randomised phase-3 trial using the same chemotherapy combination ± reovirus in SCCHN patients is therefore awaited with genuine interest.
Conclusions
OVs represent a diverse group of viruses with the ability to selectively kill tumor cells, and thus represent attractive anti-cancer agents. Pre-clinical oncolytic activity has not, thus far, been translated into routine clinical, which may reflect the inability of pre-clinical models to replicate the complexity of diverse interactions between virus tumor, and intact host immune system. It is clear that embracing existing knowledge, by encouraging anti-tumor immunity (OncoVEX GMCSF ) or exploiting synergy with chemotherapy (reovirus, ONYX-015), to enhance OV efficacy has already contributed to emerging promise, leading to late phase OV clinical trials (23, 30, 33) . Robust late phase data is required before we can accept OVs as legitimate alternatives to current therapies, however current approaches appear to be on the cusp of offering the genuine prospect of improved clinical outcomes.
Questions still remain: Is it possible, or even desirable, to overcome anti-viral immunity? Is anti-tumor immunity really more important than direct oncolysis? If so, is it possible to quantify this, and consistently to manipulate the host immune response against tumors? Synergy may offer improved response rates, but will it also lead to long-term tumor control? Is synergy also compatible with productive anti-tumor immunity? These questions may well be too complex to resolve using current preclinical models and further highlight the continuing need for in-depth translational studies, ideally in the context of OV trials. Deriving clear answers will help direct future approaches, offer enhanced therapy and could ultimately lead to improved survival for patients. Preclinical therapeutic synergy with OV is recognised across a range of tumor types and chemotherapies, and is ascribed when the Chou-Talalay combination index (CI) <1, (see main text). Underlying putative mechanisms of synergy are outlined. *Examples of clinically assessed oncolytic viruses are given in brackets; †references in superscript; ‡ this study used an alternative method to CI, to attribute synergy.
